Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)

OBJECTIVE: Friedreich ataxia (FA) is a progressive genetic neurodegenerative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA. We investigated the safety and efficacy of omaveloxol...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ann Neurol
Autores principales: Lynch, David R., Chin, Melanie P., Delatycki, Martin B., Subramony, S. H., Corti, Manuela, Hoyle, J. Chad, Boesch, Sylvia, Nachbauer, Wolfgang, Mariotti, Caterina, Mathews, Katherine D., Giunti, Paola, Wilmot, George, Zesiewicz, Theresa, Perlman, Susan, Goldsberry, Angie, O'Grady, Megan, Meyer, Colin J.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7894504/
https://ncbi.nlm.nih.gov/pubmed/33068037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25934
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares